All In Biotech

Drug Trial Radar · NCT04437160

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Platinum-based Neoadjuvant Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jun 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Feb 1, 2020

Primary completion

Jan 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Chinese Academy of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

Conditions

  • Triple Negative Breast Cancer

Interventions

  • Epirubicin or PirarubicinDrug

    Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls

  • CyclophosphamideDrug

    Cyclophosphamide 600mg/m2 IV, q21d\*4cycls

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RFSTime frame: median 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS)

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.